var data={"title":"Medroxyprogesterone acetate: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Medroxyprogesterone acetate: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6518?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=medroxyprogesterone-acetate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Medroxyprogesterone acetate: Patient drug information&quot;</a> and <a href=\"topic.htm?path=medroxyprogesterone-acetate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Medroxyprogesterone acetate: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709035\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Cardiovascular disorders (tablet):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease. The Women's Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogens (0.625 mg) combined with medroxyprogesterone acetate (2.5 mg), relative to placebo.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Breast cancer (tablet):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The Women's Health Initiative (WHI) estrogen plus progestin substudy demonstrated an increased risk of invasive breast cancer.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Dementia (tablet):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen plus progestin therapy should not be used for the prevention of dementia. The Women's Health Initiative Memory Study (WHIMS) estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years or older during 4 years of treatment with daily conjugated estrogens (0.625 mg) combined with medroxyprogesterone acetate (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Long-term use (injection):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Medroxyprogesterone contraceptive should not be used as a long-term birth control method (ie, longer than 2 years) unless other birth control methods are considered inadequate.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Loss of bone mineral density (injection):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Women who use medroxyprogesterone contraceptive may lose significant bone mineral density (BMD). Bone loss is greater with increasing duration of use and may not be completely reversible. It is unknown if use of medroxyprogesterone contraceptive during adolescence or early adulthood, a critical period of bone accretion, will reduce peak bone mass and increase the risk for osteoporotic fracture in later life.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Patient education (subcutaneous injection):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Patients should be counseled that medroxyprogesterone contraceptive does not protect against HIV infection (AIDS) and other sexually transmitted diseases.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risk vs benefits (tablet):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">In the absence of comparable data, these risks should be assumed to be similar for other doses of conjugated estrogens and medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins. Estrogens with progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192012\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Depo-Provera;</li>\n      <li>Depo-SubQ Provera 104;</li>\n      <li>Provera</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192013\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Depo-Provera;</li>\n      <li>Provera</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192035\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Contraceptive;</li>\n      <li>\n        Progestin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192015\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Abnormal uterine bleeding:</b> Oral: 5 or 10 mg daily for 5 to 10 days starting on day 16 or 21 of menstrual cycle. A suggested dose of 10 mg daily for 10 days starting on day 16 of the cycle induces optimum secretory transformation of the endometrium when adequately primed with endogenous or exogenous estrogen. Withdrawal bleeding may be expected within 3 to 7 days after discontinuing medroxyprogesterone. Planned menstrual cycling may benefit patients with a history of recurrent episodes of abnormal uterine bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Amenorrhea, secondary:</b> Oral: 5 or 10 mg daily for 5 to 10 days. Therapy may be started at any time. A dose of 10 mg daily for 10 days induces optimum secretory transformation of the endometrium when adequately primed with endogenous or exogenous estrogen. Withdrawal bleeding may be expected within 3 to 7 days after discontinuing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Contraception:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Depo-Provera Contraceptive: IM: 150 mg every 3 months (every 13 weeks)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Depo-subQ Provera 104: SubQ: 104 mg every 3 months (every 12 to 14 weeks)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endometrial carcinoma, recurrent or metastatic (adjunctive/palliative treatment):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM (Depo-Provera): Initial: 400 to 1,000 mg/week</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral (100 mg tablet [Canadian product]): Manufacturer&rsquo;s labeling: Usual dose: 200 to 400 mg daily. Doses &gt;200 mg daily may not confer additional benefit (Thigpen 1999). If improvement or disease stabilization occurs, 200 mg daily may be sufficient for maintenance. Discontinue use if no improvement within 2 to 3 months.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endometrial hyperplasia, prevention in postmenopausal persons receiving daily conjugated estrogen:</b> Oral: 5 or 10 mg once daily for 12 to 14 consecutive days each month, starting on day 1 or day 16 of the cycle. When treating postmenopausal persons, use for the shortest duration possible at the lowest effective dose consistent with treatment goals. Reevaluate patients as clinically appropriate to determine if therapy is still necessary. Progestins may be used in postmenopausal persons with a uterus to decrease the risk of endometrial cancer; persons who have had a hysterectomy generally do not need a progestin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endometrial hyperplasia, treatment (off-label use): Note: </b>The optimal duration of therapy is unknown (ACOG 631 2015; Armstrong 2012; Trimble 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Atypical endometrial hyperplasia or endometrial intraepithelial neoplasia: </i>Oral: 10 to 20 mg once daily (continuous dosing) <b>or</b> 10 mg to 20 mg once daily (cyclic dosing) for 12 to 14 days per month (ACOG 631 2015; Trimble 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Non-atypical hyperplasia:</i> Oral: 10 mg once daily (continuous dosing) (Orbo 2014) <b>or</b> 10 mg once daily (cyclic dosing) for 10 to 12 days per cycle (Abu Hashim 2016); continuous daily oral dosing was shown to be superior to cyclic oral dosing (Orbo 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endometriosis (Depo-subQ Provera 104):</b> SubQ: 104 mg every 3 months (every 12 to 14 weeks)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hot flashes (off-label use): </b>IM: 400 mg as single dose (Loprinzi 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Paraphilia/hypersexuality (off-label use) (Reilly 2000):</b> Males (<b>Note:</b> Avoid use if active pituitary pathology, hepatic failure, or thromboembolic disease):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM (Depo-Provera): 100 to 600 mg weekly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 100 to 500 mg daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192028\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=medroxyprogesterone-acetate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Medroxyprogesterone acetate: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Abnormal uterine bleeding:</b> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Amenorrhea, secondary: </b> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Contraception:</b> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Endometriosis:</b> Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192016\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16317858\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192017\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Medroxyprogesterone is extensively metabolized in the liver and elimination is significantly reduced in patients with advanced hepatic disease. Most products are contraindicated in patients with hepatic impairment. If needed for the palliative treatment metastatic endometrial carcinoma, monitor closely; withhold or discontinue treatment if liver dysfunction develops and do not resume until hepatic function has returned to normal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191989\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Intramuscular, as acetate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Depo-Provera: 150 mg/mL (1 mL); 400 mg/mL (2.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 150 mg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Prefilled Syringe, Intramuscular, as acetate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Depo-Provera: 150 mg/mL (1 mL) [contains methylparaben, polyethylene glycol, polysorbate 80, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 150 mg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Prefilled Syringe, Subcutaneous, as acetate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Depo-SubQ Provera 104: 104 mg/0.65 mL (0.65 mL) [contains methylparaben, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as acetate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Provera: 2.5 mg, 5 mg, 10 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2.5 mg, 5 mg, 10 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191974\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48850266\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suspension, IM, as acetate:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Depo-Provera: 50 mg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Oral, as acetate: 100 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191992\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Depo-Provera Contraceptive: Administer first dose during the first 5 days of menstrual period, or within the first 5 days postpartum if not breastfeeding, or at the sixth week postpartum if breastfeeding exclusively. Shake vigorously prior to administration. Administer by deep IM injection in the gluteal or deltoid muscle. Rotate administration site with each injection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">When switching from combined hormonal contraceptives (estrogen plus progestin), the first injection should be on the day after the last active tablet or (at the latest) the day after the final inactive tablet. When switching from other contraceptive methods, ensure continuous contraceptive coverage.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SubQ: Depo-subQ Provera 104: Administer first dose during the first 5 days of menstrual period, or at the sixth week postpartum if breastfeeding. Shake vigorously for at least 1 minute prior to administration. Administer by SubQ injection in the anterior thigh or abdomen; avoid boney areas and the umbilicus. Administer slowly over 5 to 7 seconds. Do not rub the injection area. Rotate administration site with each injection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">When switching from combined hormonal contraceptives (estrogen plus progestin), the first injection should be within 7 days after the last active pill, or removal of patch or ring. If switching from the IM to SubQ formulation, the next dose should be given within the prescribed dosing period for the IM injection to ensure continuous coverage.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM, SubQ: <i>Additional contraceptive considerations:</i> Available guidelines note the first injection may be given at any time in the menstrual cycle once it is determined that the woman is not pregnant. Back-up contraception is not needed if given within 7 days of onset of menstruation, immediately postpartum, or immediately after a spontaneous or induced abortion. Additional contraception is needed for 7 days unless the injection is given at the time of a surgical abortion. If the injection is given &gt;7 days after menstrual bleeding started, an additional form of contraception must be used for 7 days unless the woman abstains from sexual intercourse. When switching from an IUD to the injection in women who have had sexual intercourse since the start of their last menstrual cycle, consider postponing removal of the IUD for 7 days after the initial injection, instruct the woman to use barrier contraception or abstain from intercourse for 7 days before the first injection, or consider emergency contraception at the time of IUD removal. When contraception will be continued, repeat injections should be given every 13 weeks but may be given early if needed. Injections may be given up to 2 weeks late, however pregnancy should be ruled out and additional contraceptive measures are required for 7 days if the repeat dose is &gt;15 weeks from the last injection (Curtis 2016a).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132797\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. For injectable products, NIOSH recommends double gloving, a protective gown, and ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator) for preparation. Double gloving and a protective gown are required during IM or subcutaneous administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191991\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Abnormal uterine bleeding (tablet):</b> Treatment of abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Amenorrhea, secondary (tablet):</b> Treatment of secondary amenorrhea due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Contraception (104 mg/0.65 mL and 150 mg/mL injection):</b> Prevention of pregnancy in women of childbearing potential.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endometrial hyperplasia prevention (tablet):</b> Prevention of endometrial hyperplasia in nonhysterectomized postmenopausal persons receiving daily oral conjugated estrogens 0.625 mg.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endometrial carcinoma (400 mg/mL injection) (100 mg tablet [Canadian product]):</b> Adjunctive therapy and/or palliative treatment of inoperable, recurrent, and/or metastatic endometrial carcinoma.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endometriosis (104 mg/0.65 mL injection):</b> Management of endometriosis-associated pain.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25730742\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Endometrial hyperplasia (treatment); Hot flashes (intramuscular administration); Paraphilia/hypersexuality (treatment)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192043\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Depo-Provera may be confused with DEPO-Medrol, depo-subQ provera 104</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MedroxyPROGESTERone may be confused with HYDROXYprogesterone caproate, methylPREDNISolone, methylTESTOSTERone </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Provera may be confused with Covera, Femara, Parlodel, Premarin, Proscar, PROzac</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The injectable dosage form is available in different formulations. Carefully review prescriptions to assure the correct formulation and route of administration.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191981\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects as reported with any dosage form.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (9% to 17%), nervousness (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Amenorrhea (IM: 55% at 12 months; 68% at 24 months; SubQ: 6%), weight gain (IM: &gt;10 lbs at 24 months: 38%; SubQ: 6%), menstrual disease (IM: 57% at 12 months; 32% at 24 months; SubQ: 1% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (1% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Edema (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (1% to 6%), anxiety (1% to &lt;5%), depression (1% to &lt;5%), insomnia (1% to &lt;5%), irritability (1% to &lt;5%), fatigue (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Acne vulgaris (1% to &lt;5%), alopecia (1%), skin rash (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Decreased libido (1% to 6%), change in menstrual flow (menometrorrhagia; 1% to &lt;5%), hypermenorrhea (1% to &lt;5%), hot flash (1% to &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal distension (1% to &lt;5%), diarrhea (1% to &lt;5%), nausea (1% to &lt;5%), bloating (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Abnormal Pap smear (1% to &lt;5%), bacterial vaginosis (1% to &lt;5%), breast tenderness (1% to &lt;5%), dysmenorrhea (1% to &lt;5%), mastalgia (1% to &lt;5%), urinary tract infection (1% to &lt;5%), uterine hemorrhage (1% to &lt;5%), vaginal hemorrhage (1% to &lt;5%), vaginitis (1% to &lt;5%), vulvovaginal candidiasis (1% to &lt;5%), leukorrhea (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (1% to &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Pain at injection site (1% to &lt;5%), atrophy at injection site (&le;1%), induration at injection site (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (1% to &lt;5%), back pain (1% to &lt;5%), limb pain (1% to &lt;5%), leg cramps (4%), weakness (&le;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Bronchitis (1% to &lt;5%), nasopharyngitis (1% to &lt;5%), pharyngitis (1% to &lt;5%), sinusitis (1% to &lt;5%), upper respiratory tract infection (1% to &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Euphoria, malaise</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Cushing syndrome, hypercalcemia, lipodystrophy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Breakthrough bleeding, spotting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site nodule, tenderness at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, anaphylactoid reaction, anemia, angioedema, anxiety, asthma, axillary swelling, Bell palsy, body odor, breast changes, cervical cancer, change in appetite, change in cervical erosion, change in cervical secretions, chest pain, chills, chloasma, cholestatic jaundice, decreased bone mineral density, decreased glucose tolerance, decreased lactation, deep vein thrombosis, delayed return to fertility, diaphoresis, drowsiness, dyspareunia, dyspnea, fever, galactorrhea, genitourinary infection, hematologic abnormality, hirsutism, hoarseness, hypersensitivity reaction, increased libido, increased thirst, jaundice, lump in breast, malignant neoplasm of breast, nipple bleeding, nipple discharge, oligomenorrhea, optic neuritis, osteoporosis, paralysis, paresthesia, pathological fracture due to osteoporosis, pruritus, pulmonary embolism, rectal hemorrhage, residual mass at injection site, retinal thrombosis, scleroderma, seizure, skin discoloration (melasma), skin discoloration at injection site, sterile abscess at injection site, syncope, tachycardia, thrombophlebitis, urticaria, uterine hyperplasia, vaginal cyst, varicose veins, weight loss, xeroderma</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191995\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection (104 mg/0.65 mL): Hypersensitivity to medroxyprogesterone or any component of the formulation; active thrombophlebitis; thromboembolic disorders (current or history of); cerebral vascular disease; undiagnosed vaginal bleeding; breast cancer (known, suspected, or history of); significant hepatic disease; pregnancy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection (150 mg/mL): Hypersensitivity to medroxyprogesterone or any component of the formulation; active thrombophlebitis; thromboembolic disorders (current or history of) or cerebral vascular disease; undiagnosed vaginal bleeding; breast cancer (known, suspected, or history of); significant hepatic disease; pregnancy; diagnostic test for pregnancy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection (400 mg/mL): Hypersensitivity to medroxyprogesterone or any component of the formulation; active thrombophlebitis; thromboembolic disorders (current or history of); cerebral vascular disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet: Anaphylactic reaction or angioedema to medroxyprogesterone; DVT or PE (current or history of); active or history of arterial thromboembolic disease (eg, stroke, MI); estrogen- or progesterone-dependent tumor (known or suspected) (excludes 100 mg tablet [Canadian product] indicated for endometrial cancer); undiagnosed abnormal genital bleeding; breast cancer (known, suspected, or history of); hepatic impairment or disease; pregnancy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Injection (50 mg/mL, 104 mg per 0.65 mL, 150 mg/mL): History of or current benign or malignant liver tumors; current or history of migraine with focal aura; any ocular lesion arising from ophthalmic vascular disease, such as partial or complete loss of vision or defect in visual fields; undiagnosed breast pathology; known or suspected progestin-dependent neoplasia; MI or coronary artery disease (current or history of); urinary tract bleeding; presence of severe or multiple risk factors for arterial or venous thrombosis including the following: severe hypertension (persistent bp &ge;160/100 mm Hg); hereditary or acquired predisposition for venous or arterial thrombosis (eg, Factor V leiden and Prothrombin G20210 A mutation, activated protein C (APC) resistance, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinanemia and antiphospholipid-antibodies (anticardiolipin antibodies, lupus anticoagulant); severe dyslipoproteinemia; heavy smoking (&gt;15 cigarettes per day) and older than 35 years of age; diabetes mellitus with vascular involvement</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet: Partial or complete loss of vision due to ophthalmic vascular disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191978\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal suppression: May cause suppression of hypothalamic-pituitary-adrenal (HPA) axis, resulting in decreased plasma cortisol concentrations, decreased cortisol secretion, and low plasma ACTH concentrations. Cushingoid symptoms may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis/hypersensitivity reactions: Anaphylaxis or anaphylactoid reactions have been reported with use of the injection; medication for the treatment of hypersensitivity reactions should be available for immediate use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone mineral density loss: <b>[US Boxed Warning]: Prolonged use of medroxyprogesterone contraceptive injection may result in a loss of bone mineral density (BMD). It is not known if use during adolescence or early adulthood will decrease peak bone mass accretion or increase the risk for osteoporotic fractures later in life. Loss is related to the duration of use, may not be completely reversible on discontinuation of the drug,</b> and incidence is not significantly different between the SubQ and IM dosage forms. The impact on peak bone mass in adolescents should be weighed against the potential for unintended pregnancies in treatment decision. Consider alternative contraceptive methods in patients at risk for osteoporosis (eg, metabolic bone disease, chronic alcohol and/or tobacco use, anorexia nervosa, strong family history of osteoporosis, chronic use of medications associated with osteoporosis such as anticonvulsants or corticosteroids). All patients should have adequate calcium and Vitamin D intake. Consider evaluating bone mineral density in patients receiving high doses of medroxyprogesterone for long term endometrial cancer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Breast cancer: <b>[US Boxed Warning]: Based on data from the Women's Health Initiative (WHI) studies, an increased risk of invasive breast cancer was observed in postmenopausal women using conjugated estrogens (CE) in combination with medroxyprogesterone acetate (MPA).</b> This risk may be associated with duration of use and declines once combined therapy is discontinued (Chlebowski 2009). The risk of invasive breast cancer was decreased in postmenopausal women with a hysterectomy using CE only, regardless of weight. However, the risk was not significantly decreased in women at high risk for breast cancer (family history of breast cancer, personal history of benign breast disease) (Anderson 2012). Women who used depo-medroxyprogesterone within the previous 5 years and for a duration of 12 months or longer were found to have an increased risk of breast cancer. An increase in abnormal mammogram findings has also been reported with estrogen alone or in combination with progestin therapy. Most products are contraindicated in patients with known or suspected breast cancer. Use of medroxyprogesterone for the treatment of endometrial carcinoma is not recommended in women with known or suspected breast cancer and women with a strong family history of breast cancer should be carefully monitored.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dementia: <b>[US Boxed Warning]: Estrogens with or without progestin should not be used to prevent dementia. In the Women's Health Initiative Memory Study (WHIMS), an increased incidence of probable dementia was observed in women &ge;65 years of age taking CE in combination with MPA.</b> The risk to younger postmenopausal persons is not known.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ectopic pregnancy: When used for contraception, the possibility of ectopic pregnancy should be considered in patients with severe abdominal pain.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Endometrial cancer: MPA is used to reduce the risk of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving conjugated estrogens. The use of unopposed estrogen in women with a uterus is associated with an increased risk of endometrial cancer. The addition of a progestin to estrogen therapy may decrease the risk of endometrial hyperplasia, a precursor to endometrial cancer. Adequate diagnostic measures, including endometrial sampling if indicated, should be performed to rule out malignancy in postmenopausal women with undiagnosed abnormal vaginal bleeding. There is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens at equivalent estrogen doses. The risk of endometrial cancer is dose and duration dependent; risk appears to be greatest with use &ge;5 years and may persist following discontinuation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertriglyceridemia: In women using estrogen plus progesterone therapy, triglycerides may be increased in women with preexisting hypertriglyceridemia; discontinue if pancreatitis occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ovarian cancer: Postmenopausal estrogen therapy and combined estrogen/progesterone therapy may increase the risk of ovarian cancer; however, the absolute risk to an individual woman is small. Although results from various studies are not consistent, risk does not appear to be significantly associated with the duration, route, or dose of therapy. In one study, the risk decreased after 2 years following discontinuation of therapy (M&oslash;rch, 2009). Although the risk of ovarian cancer is rare, women who are at an increased risk (eg, family history) should be counseled about the association (NAMS2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Retinal vascular thrombosis: Discontinue pending examination in cases of sudden partial or complete vision loss, sudden onset of proptosis, diplopia, or migraine; discontinue permanently if papilledema or retinal vascular lesions are observed on examination.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaginal bleeding: Unscheduled bleeding/spotting may occur. Presentation of irregular, unresolving vaginal bleeding following previously regular cycles warrants further evaluation including endometrial sampling, if indicated, to rule out malignancy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Weight gain: Contraceptive therapy with medroxyprogesterone commonly results in an average weight gain of ~3.7 kg after 2 years of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asthma: Use estrogen plus progestin therapy with caution in patients with asthma; may exacerbate disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: <b>[US Boxed Warning]: Estrogens with progestin should not be used to prevent cardiovascular disease. Using data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of deep vein thrombosis (DVT), pulmonary emboli (PE), and stroke has been reported with CE 0.625 mg with MPA 2.5 mg in postmenopausal women 50 to 79 years.</b> Additional risk factors include diabetes mellitus, hypercholesterolemia, hypertension, SLE, obesity, tobacco use, and/or history of venous thromboembolism (VTE). Risk factors should be managed appropriately; discontinue use if adverse cardiovascular events occur or are suspected. Use is contraindicated in women with active DVT, PE, arterial thromboembolic disease or a history of these conditions. When used for contraception, use caution in patients with risk factors for cardiovascular disease (Curtis 2016b). If thrombosis develops with contraceptive treatment, discontinue treatment (unless no other acceptable contraceptive alternative).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Depression: Use with caution in patients with a history of depression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Estrogen plus progestin therapy may have adverse effects on glucose tolerance; use caution in women with diabetes mellitus.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diseases exacerbated by fluid retention: Use with caution in patients with diseases which may be exacerbated by fluid retention, including cardiac or renal dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Epilepsy: Use estrogen plus progestin therapy with caution in patients with epilepsy; may exacerbate disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic dysfunction: Estrogens plus progestins are poorly metabolized in patients with hepatic dysfunction. Use caution with a history of cholestatic jaundice associated with prior estrogen use or pregnancy. Discontinue if jaundice develops or if acute or chronic hepatic disturbances occur. Most products are contraindicated with hepatic impairment or disease. Use of medroxyprogesterone for the treatment of endometrial carcinoma is not recommended in women with significant hepatic dysfunction and should be discontinued if liver dysfunction occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic hemangiomas: Use estrogen plus progestin therapy with caution in patients with hepatic hemangiomas; may exacerbate disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypoparathyroidism: Use estrogen plus progestin therapy with caution in patients with hypoparathyroidism; estrogen-induced hypocalcemia may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Migraine: Use caution in patients with migraine; may exacerbate disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Porphyria: Use estrogen plus progestin therapy with caution in patients with porphyria; may exacerbate disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Systemic lupus erythematosus: Use estrogen plus progestin therapy with caution in patients with systemic lupus erythematosus (SLE); may exacerbate disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Menopause: Use may mask the onset of menopause in women treated for endometrial cancer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Not for use prior to menarche.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgical patients: Whenever possible, progestins in combination with estrogens should be discontinued at least 4 to 6 weeks prior to surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley, 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; HIV infection protection: <b>[US Boxed Warning]: Inform patients that injectable contraceptives do not protect against HIV infection or other sexually transmitted diseases.</b> Women at high risk for HIV infection should be informed that there may be an increased risk of acquiring HIV with use of a progestin-only injection contraceptive. However, available data are inconsistent, and benefits of use may outweigh potential risk; treatment should not be withheld when appropriate. Women should be instructed about HIV prevention measures (Tepper 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Laboratory changes: The use of estrogens and/or progestins may change the results of some laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). The dose, route, and the specific estrogen/progestin influences these changes. In addition, personal risk factors (eg, cardiovascular disease, smoking, diabetes, age) also contribute to adverse events; use of specific products may be contraindicated in women with certain risk factors.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Long-term use: <b>[US Boxed Warning]: Long-term use (ie, &gt;2 years) should be limited to situations where other birth control methods are inadequate.</b> When used for endometrial carcinoma, the effects of long term use on adrenal, hepatic, ovarian, pituitary, and uterine function is not known.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Risks vs benefits: <b>[US Boxed Warning]: Estrogens with progestin should be used for the shortest duration possible at the lowest effective dose consistent with treatment goals and risks for the individual woman.</b> Patients should be reevaluated as clinically appropriate to determine if treatment is still necessary. Available data related to treatment risks are from Women&rsquo;s Health Initiative (WHI) studies, which evaluated oral CE 0.625 mg with or without MPA 2.5 mg relative to placebo in postmenopausal women. Other combinations and dosage forms of estrogens and progestins were not studied. <b>Outcomes reported from clinical trials using CE with or without MPA should be assumed to be similar for other doses and other dosage forms of estrogens and progestins until comparable data becomes available.</b> Women who are early in menopause, who are in good cardiovascular health, and who are at low risk for adverse cardiovascular events can be considered candidates for estrogen with or without progestin therapy for the relief of menopausal symptoms (ACOG 565 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192030\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191983\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9600&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acitretin: May diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible. Management: Given the potential for progestin-only preparations to fail to prevent pregnancy during acitretin therapy, such products should not be relied upon. Alternative, nonhormonal forms of contraception must be employed during acitretin therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Progestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.  Management: Carefully weigh the prospective benefits of progestins against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May decrease the serum concentration of Progestins (Contraceptive). Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Artemether: May decrease the serum concentration of Progestins (Contraceptive). Management: Consider the use of an alternative (i.e., non-hormonal) means of contraception in all women of childbearing potential who are using artemether.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atazanavir: May increase the serum concentration of Progestins (Contraceptive). However, atazanavir may lead to decreased ethinyl estradiol concentrations and decreased effectiveness of oral contraceptive products. Management: Consider an alternative or additional method of contraception, particularly with combined estrogen/progestin products. Depot medroxyprogesterone acetate may be used without a need for additional contraception.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bexarotene (Systemic): May decrease the serum concentration of Progestins (Contraceptive). Management: Women of childbearing potential receiving bexarotene should use two reliable forms of contraception (including at least one nonhormonal form).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the serum concentration of Progestins (Contraceptive). Management: Administer oral progestin-containing contraceptives at least 1 to 4 hours prior to or 4 to 6 hours after administration of a bile acid sequestrant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: May increase the serum concentration of Progestins (Contraceptive). This has been seen specifically with drospirenone. Boceprevir may increase the serum concentration of Progestins (Contraceptive). This has been seen specifically with norethindrone. Management: Patients receiving boceprevir, ribavirin, and peginterferon alfa should use two reliable forms of contraception.  Norethindrone/ethinyl estradiol may be used for one of these when norethindrone dose is at least 1 mg/day. Avoid drospirenone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of Progestins (Contraceptive). Management: Use an alternative (i.e., non-hormonal) means of contraception for all women of childbearing potential who are using bosentan, and do not rely on hormonal contraceptives alone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: May decrease the serum concentration of Progestins (Contraceptive). Management: Females of childbearing potential should use an alternative, non-hormonal contraceptive during brigatinib therapy and for at least 4 months after the final brigatinib dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">C1 inhibitors: Progestins may enhance the thrombogenic effect of C1 inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carfilzomib: May enhance the thrombogenic effect of Progestins (Contraceptive). Management: Consider alternative, non-hormonal methods of contraception in patients requiring therapy with carfilzomib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Choline C 11: Antiandrogens may diminish the therapeutic effect of Choline C 11. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloBAZam: May decrease the serum concentration of Progestins (Contraceptive).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of Progestins (Contraceptive). Management: Consider an alternative, non-hormone-based contraceptive in patients receiving cobicistat-containing products. Drospirenone is specifically contraindicated with atazanavir and cobicistat.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of MedroxyPROGESTERone.<b> Exceptions: </b>Atazanavir; Boceprevir; Cobicistat; Darunavir; Lopinavir; Nelfinavir; Saquinavir; Telaprevir.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of Progestins (Contraceptive). Management: Females of reproductive potential should use an alternative, highly effective, non-hormonal means of contraception during and at least 2 weeks (dabrafenib alone) or 4 months (dabrafenib + trametinib) after discontinuation of dabrafenib treatment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: May decrease the serum concentration of Progestins (Contraceptive). Management: Consider using an alternative or additional means of contraception.  Injected depot medroxyprogesterone acetate may be used without a need for additional contraception.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efavirenz: May decrease the serum concentration of Progestins (Contraceptive). Management: Use an alternative or additional method of contraception due to possibly decreased contraceptive effectiveness. Injected depot medroxyprogesterone acetate does not appear to participate in this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eslicarbazepine: May decrease the serum concentration of Progestins (Contraceptive). Management: Alternative, non-hormonal means of birth control should be considered for women of child-bearing potential.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Felbamate: May decrease the serum concentration of Progestins (Contraceptive). Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal method of contraception is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: Progestins (Contraceptive) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosamprenavir: Progestins (Contraceptive) may decrease serum concentrations of the active metabolite(s) of Fosamprenavir. Fosamprenavir may decrease the serum concentration of Progestins (Contraceptive).  Management: Consider using an alternative or additional means of contraception.  Injected depot medroxyprogesterone acetate may be used without a need for additional contraception.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May decrease the serum concentration of Progestins (Contraceptive). The active metabolite aprepitant is likely responsible for this effect. Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Griseofulvin: May diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Progestogenic Properties) (eg, Bloodroot, Yucca): May enhance the adverse/toxic effect of Progestins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indium 111 Capromab Pendetide: Antiandrogens may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ixazomib: May decrease the serum concentration of Progestins (Contraceptive). More specifically, use of ixazomib with dexamethasone may decrease the serum concentrations of contraceptive progestins. Management: Patients of childbearing potential should use a nonhormonal barrier contraceptive during and 90 days following ixazomib treatment.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LamoTRIgine: May decrease the serum concentration of Progestins (Contraceptive).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lesinurad: May decrease the serum concentration of Progestins (Contraceptive). Management: Use of an additional, nonhormonal contraceptive is recommended in patients being treated with lesinurad who desire effective contraception.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lixisenatide: May decrease the serum concentration of Progestins (Contraceptive). Management: Administer oral contraceptives 1 hour before or at least 11 hours after administration of lixisenatide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lopinavir: May decrease the serum concentration of Progestins (Contraceptive). Lopinavir may increase the serum concentration of Progestins (Contraceptive). Management: Consider using an alternative or additional means of contraception.  Injected depot medroxyprogesterone acetate and etonogestrel implants may be used without a need for additional contraception.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of Progestins (Contraceptive). Management: Do not rely on hormone-based contraceptives with concurrent use of lumacaftor/ivacaftor; an alternative, non-hormonal, method of contraception should be used if this combination is required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metreleptin: May decrease the serum concentration of Progestins (Contraceptive). Metreleptin may increase the serum concentration of Progestins (Contraceptive).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May diminish the therapeutic effect of Progestins (Contraceptive). MiFEPRIStone may increase the serum concentration of Progestins (Contraceptive). Management: Women of childbearing potential should use an effective, nonhormonal means of contraception during and 4 weeks following mifepristone treatment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: May decrease the serum concentration of Progestins (Contraceptive). Management: Use of an additional or alternative (nonhormonal) method of contraception should be considered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nalmefene: MedroxyPROGESTERone may increase the serum concentration of Nalmefene. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nelfinavir: May decrease the serum concentration of Progestins (Contraceptive). Management: Use an alternative or additional method of contraception due to possibly decreased contraceptive effectiveness. Injected depot medroxyprogesterone acetate does not appear to participate in this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nevirapine: May decrease the serum concentration of Progestins (Contraceptive). Management: Instruct patients receiving nevirapine to use an alternative or additional nonhormonal contraceptive. Nevirapine product labeling however suggests that depo-medroxyprogesterone acetate may be used as a sole method of contraception.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OXcarbazepine: May decrease the serum concentration of Progestins (Contraceptive). Management: Contraceptive failure is possible.  Use of an additional or alternative, nonhormonal method of contraception is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May decrease the serum concentration of Progestins (Contraceptive). Management: Patients should use an alternative, nonhormonal-based form of contraception both during the concurrent use of perampanel and for 1 month after discontinuing perampanel.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May diminish the therapeutic effect of Progestins (Contraceptive). Management: The combination of hormonal contraceptives with pitolisant should be avoided, and an alternate means of contraception should be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pomalidomide: Progestins may enhance the thrombogenic effect of Pomalidomide.  Management: Canadian pomalidomide labeling recommends caution with use of hormone replacement therapy and states that hormonal contraceptives are not recommended. US pomalidomide labeling does not contain these specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Primidone: May diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prucalopride: May decrease the serum concentration of Progestins (Contraceptive).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Retinoic Acid Derivatives: May diminish the therapeutic effect of Progestins (Contraceptive). Retinoic Acid Derivatives may decrease the serum concentration of Progestins (Contraceptive). Management: Two forms of effective contraception should be used in patients receiving retinoic acid derivatives.  Particularly, microdosed progesterone-only preparations may be inadequately effective.<b> Exceptions: </b>Adapalene; Bexarotene (Topical); Tretinoin (Topical).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May decrease the serum concentration of Progestins (Contraceptive). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saquinavir: May decrease the serum concentration of Progestins (Contraceptive). Management: Use an alternative or additional method of contraception due to possibly decreased contraceptive effectiveness. Injected depot medroxyprogesterone acetate does not appear to participate in this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selegiline: Progestins (Contraceptive) may increase the serum concentration of Selegiline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible. Management: Consider using a product other than St John's wort.  Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sugammadex: May decrease the serum concentration of Progestins (Contraceptive). Management: Patients receiving any hormonal contraceptive (oral or non-oral) should use an additional, nonhormonal contraceptive method during and for 7 days following sugammadex treatment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May decrease the serum concentration of Progestins (Contraceptive). Management: Two different nonhormonal forms of contraception are required for women of childbearing potential taking telaprevir.  Hormonal contraceptives may be less effective during concurrent telaprevir and for up to 2 weeks after telaprevir discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: Progestins (Contraceptive) may enhance the thrombogenic effect of Thalidomide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May increase the serum concentration of Progestins (Contraceptive). Management: Use an alternative or additional method of contraception due to possibly decreased contraceptive effectiveness. Injected depot medroxyprogesterone acetate does not appear to participate in this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topiramate: May decrease the serum concentration of Progestins (Contraceptive). Management: Caution patients that this combination may be associated with reduced contraceptive effectiveness.  Consider adding an additional (non-hormonal) contraceptive method.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tranexamic Acid: Progestins (Contraceptive) may enhance the thrombogenic effect of Tranexamic Acid. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ulipristal: Progestins may diminish the therapeutic effect of Ulipristal. Ulipristal may diminish the therapeutic effect of Progestins.  Management: Ulipristal for uterine fibroids (Canadian indication): avoid progestins within 12 days of stopping ulipristal; as emergency contraceptive (U.S. indication): avoid progestins within 5 days of stopping ulipristal.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Progestins (Contraceptive) may diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products.  Management: When possible, concomitant hormonal contraceptives and coumarin derivatives should be avoided in order to eliminate the risk of thromboembolic disorders.  Consider using an alternative, nonhormonal contraceptive.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: May increase the serum concentration of Progestins (Contraceptive). Progestins (Contraceptive) may increase the serum concentration of Voriconazole.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192007\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Bioavailability of the oral tablet is increased when taken with food; half-life is unchanged. Management: Administer without regard to food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191997\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Most products are contraindicated in women who are pregnant, suspected to be pregnant or as a diagnostic test for pregnancy. In general, there is not an increased risk of birth defects following inadvertent use of the injectable medroxyprogesterone acetate (MPA) contraceptives early in pregnancy. Hypospadias has been reported in male babies and clitoral enlargement and labial fusion have been reported in female babies exposed to MPA during the first trimester of pregnancy. High doses impair fertility. Ectopic pregnancies have been reported with use of the MPA contraceptive injection. Median time to conception/return to ovulation following discontinuation of MPA contraceptive injection is 10 months following the last injection and is unrelated to the duration of use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191998\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Medroxyprogesterone acetate (MPA) is present in breast milk. Composition, quality, and quantity of breast milk are not affected; adverse developmental and behavioral effects have not been noted following exposure of infant to MPA while breastfeeding. The manufacturer does not recommend the use of MPA tablets in breastfeeding mothers; however, guidelines note that the injectable MPA contraceptives can be initiated immediately postpartum in women who are breastfeeding (Curtis 2016a; Curtis 2016b). The manufacturer recommends medroxyprogesterone 400 mg/mL be used with caution in women who are breastfeeding.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191999\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Ensure adequate calcium and vitamin D intake</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191987\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monitor patient closely for loss of vision; sudden onset of proptosis, diplopia, or migraine; signs and symptoms of thromboembolic disorders; signs or symptoms of depression; glucose in patients with diabetes; or blood pressure. Adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding. Monitor blood pressure at regular intervals with estrogen plus progestin therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Contraception: Assessment of pregnancy status (prior to therapy); weight (optional; BMI at baseline may be helpful to monitor changes during therapy); assess potential health status changes at routine visits (Curtis 2016a). BMD with long-term use (per manufacturer).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endometrial cancer: Consider BMD with long term use; breast cancer (in women with a strong family history of breast cancer).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endometrial hyperplasia, treatment (off-label use): Endometrial sampling every 3 to 6 months, although most appropriate frequency has not been determined (ACOG 631 2015; Trimble 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Treatment of paraphilia/hypersexuality (Guay 2009; Reilly, 2000): Hepatic function test (baseline and during treatment if suspected hepatotoxicity); CBC (baseline); serum testosterone (baseline then monthly for 4 months then every 6 months); serum LH and prolactin (baseline and every 6 months); FSH (baseline); glucose; bone scan (baseline then annually) if serum testosterone significantly suppressed; gallbladder function; blood pressure; weight gain</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191977\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Medroxyprogesterone acetate (MPA) transforms a proliferative endometrium into a secretory endometrium. When administered with conjugated estrogens, MPA reduces the incidence of endometrial hyperplasia and risk of adenocarcinoma. When used as an injection for contraception (doses of 150 mg IM or 104 mg SubQ), MPA inhibits secretion of pituitary gonadotropins, which prevents follicular maturation and ovulation and causes endometrial thinning. Progestogens, such as medroxyprogesterone when used for endometriosis, lead to atrophy of the endometrial tissue. They may also suppress new growth and implantation. Pain associated with endometriosis is decreased (ASRM 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191994\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Time to ovulation (after last injection): 10 months (range: 6 to 12 months)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Rapid; IM: Slow</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 86% to 90% primarily to albumin; does not bind to sex hormone-binding globulin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Extensively hepatic via hydroxylation and conjugation; forms metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: 0.6% to 10%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Oral: 12 to 17 hours; IM (Depo-Provera Contraceptive): ~50 days; SubQ: ~43 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Oral: 2 to 4 hours; IM (Depo-Provera Contraceptive): ~3 weeks; SubQ: ~1 week</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191996\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Depo-Provera Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg/mL (1 mL): $250.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg/mL (2.5 mL): $646.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (MedroxyPROGESTERone Acetate Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg/mL (1 mL): $97.85</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension Prefilled Syringe</b> (Depo-Provera Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg/mL (1 mL): $239.74</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension Prefilled Syringe</b> (Depo-SubQ Provera 104 Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">104 mg/0.65 mL (0.65 mL): $280.15</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension Prefilled Syringe</b> (MedroxyPROGESTERone Acetate Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg/mL (1 mL): $66.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (MedroxyPROGESTERone Acetate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (100): $31.29</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $47.25</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $49.14</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Provera Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (100): $300.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $451.86</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $589.49</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192000\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Climanor (GB, IE, TR);</li>\n      <li>Clinofem (DE);</li>\n      <li>Condep (MY);</li>\n      <li>Cycrin (AR, NZ);</li>\n      <li>DB-10 (PH);</li>\n      <li>Depo Progestin (ID);</li>\n      <li>Depo Provera (LK);</li>\n      <li>Depo-M (TH);</li>\n      <li>Depo-Prodasone (FR);</li>\n      <li>Depo-Provera (AE, AU, BB, BH, CN, CR, CY, DO, EG, ET, GT, HN, IE, IL, IQ, IR, JO, KW, LB, LY, NI, OM, PA, PH, QA, SA, SG, SV, SY, UA, VN, YE);</li>\n      <li>Depo-Ralovera (AU);</li>\n      <li>Depofemme (PH);</li>\n      <li>Depomoxie (TH);</li>\n      <li>Deponeo (ID);</li>\n      <li>Deporeva (PH);</li>\n      <li>Depotrust (PH);</li>\n      <li>Deviry (LK);</li>\n      <li>Enaf-150 (TH);</li>\n      <li>Farlutal (AE, BE, BR, CN, CY, EG, ES, FR, IQ, IR, IT, JO, KR, KW, LB, LY, NL, OM, QA, SA, SY, TR, YE);</li>\n      <li>Farlutal Depot (BH, EG, QA);</li>\n      <li>GestaPolar (DE);</li>\n      <li>Gestapuran (FI, SE);</li>\n      <li>Livomedrox (PY);</li>\n      <li>Lyndavel (PH);</li>\n      <li>Manodepo (TH);</li>\n      <li>Medogen (BD);</li>\n      <li>Medrina (BD);</li>\n      <li>Medrone (TW);</li>\n      <li>Medroxine (UY);</li>\n      <li>Megestron (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Meprate (IN);</li>\n      <li>Meterone (TW);</li>\n      <li>Miprox (LK);</li>\n      <li>Movera (BD);</li>\n      <li>MPA Gyn 5 (DE);</li>\n      <li>Non-Preg (TH);</li>\n      <li>Perlutex (AE, BM, BS, BZ, DK, GY, JM, SR, TT);</li>\n      <li>Petogen (ET, ZW);</li>\n      <li>Prodafem (AT, CH);</li>\n      <li>Progen (KR);</li>\n      <li>Progevera (ES);</li>\n      <li>Provenor (BD);</li>\n      <li>Provera (AE, AU, BB, BD, BE, BF, BG, BH, BJ, BR, CI, CL, CN, CO, CR, CY, CZ, DK, DO, EC, EE, EG, ET, FI, GB, GH, GM, GN, GR, GT, HK, HN, HR, ID, IE, IL, IN, IQ, IR, IT, JO, KE, KR, KW, LB, LK, LR, LU, LV, LY, MA, ML, MR, MT, MU, MW, MX, NE, NG, NI, NL, NO, NZ, OM, PA, PE, PH, PL, PT, QA, SA, SC, SD, SE, SG, SI, SK, SL, SN, SV, SY, TH, TN, TW, TZ, UG, VE, VN, YE, ZA, ZM, ZW);</li>\n      <li>Provera LD (MY);</li>\n      <li>Ralovera (AU);</li>\n      <li>Ravimed (MY);</li>\n      <li>Sayana (IL, KR);</li>\n      <li>Sayana Press (GB);</li>\n      <li>Triclovera (ET);</li>\n      <li>Veraplex (ID, RU, TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25797236\"></a>Abu Hashim H, Ghayaty E, El Rakhawy M. Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: a systematic review and metaanalysis of randomized trials. <i>Am J Obstet Gynecol</i>. 2015;213(4):469-478.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/medroxyprogesterone-acetate-drug-information/abstract-text/25797236/pubmed\" target=\"_blank\" id=\"25797236\">25797236</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee Opinion No. 565: Hormone therapy and heart disease. <i>Obstet Gynecol</i>. 2013;121:1407-1410.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/medroxyprogesterone-acetate-drug-information/abstract-text/23812486/pubmed\" target=\"_blank\" id=\"23812486\">23812486</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/medroxyprogesterone-acetate-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25932867\"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Gynecologic Practice, Society of Gynecologic Oncology. The American College of Obstetricians and Gynecologists Committee Opinion no. 631. Endometrial intraepithelial neoplasia. <i>Obstet Gynecol</i>. 2015;125(5):1272-1278. doi: 10.1097/01.AOG.0000465189.50026.20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/medroxyprogesterone-acetate-drug-information/abstract-text/25932867/pubmed\" target=\"_blank\" id=\"25932867\">25932867</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson GL, Chlebowski RT, Aragaki AK, et al, &quot;Conjugated Equine Oestrogen and Breast Cancer Incidence and Mortality in Postmenopausal Women With Hysterectomy: Extended Follow-Up of the Women's Health Initiative Randomised Placebo-Controlled Trial,&quot; <i>Lancet Oncol,</i> 2012,13(5):476-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/medroxyprogesterone-acetate-drug-information/abstract-text/22401913/pubmed\" target=\"_blank\" id=\"22401913\">22401913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson GL, Limacher M, Assaf AR, et al, &quot;Effects of Conjugated Equine Estrogen In Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial.&quot; <i>JAMA</i>, 2004, 291(14):1701-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/medroxyprogesterone-acetate-drug-information/abstract-text/15082697/pubmed\" target=\"_blank\" id=\"15082697\">15082697</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Apo-Medroxy (medroxyprogesterone) [product monograph]. Toronto, Ontario, Canada: Apotex Inc; March 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22863972\"></a>Armstrong AJ, Hurd WW, Elguero S, et al. Diagnosis and management of endometrial hyperplasia. <i>J Minim Invasive Gynecol</i>. 2012;19(5):562-571.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/medroxyprogesterone-acetate-drug-information/abstract-text/22863972/pubmed\" target=\"_blank\" id=\"22863972\">22863972</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/medroxyprogesterone-acetate-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chlebowski RT, Kuller LH, Prentice RL, et al, &quot;Breast Cancer After Use of Estrogen Plus Progestin in Postmenopausal Women,&quot; <i>N Engl J Med</i>, 2009, 360(6):573-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/medroxyprogesterone-acetate-drug-information/abstract-text/19196674/pubmed\" target=\"_blank\" id=\"19196674\">19196674</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27467319\"></a>Curtis KM, Jatlaoui TC, Tepper NK, et al. US selected practice recommendations for contraceptive use, 2016. <i>MMWR Recomm Rep</i>. 2016a;65(4):1&#8208;66. doi: 10.15585/mmwr.rr6504a1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/medroxyprogesterone-acetate-drug-information/abstract-text/27467319/pubmed\" target=\"_blank\" id=\"27467319\">27467319</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27467196\"></a>Curtis KM, Tepper NK, Jatlaoui TC, et al. US medical eligibility criteria for contraceptive use, 2016. <i>MMWR Recomm Rep</i>. 2016b;65(3):1&#8208;103. doi: 10.15585/mmwr.rr6503a1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/medroxyprogesterone-acetate-drug-information/abstract-text/27467196/pubmed\" target=\"_blank\" id=\"27467196\">27467196</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Depo-Provera (medroxyprogesterone acetate) [prescribing information]. New York, NY: Pfizer; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Depo-Provera (medroxyprogesterone acetate) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Depo-Provera CI (medroxyprogesterone acetate) [prescribing information]. New York, NY: Pfizer; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    depo-subQ provera 104 (medroxyprogesterone acetate) [prescribing information]. New York, NY: Pfizer; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gagne P, &ldquo;Treatment of Sex Offenders With Medroxyprogesterone Acetate,&rdquo; <i>Am J Psychiatry</i>, 1981, 138(5):644-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/medroxyprogesterone-acetate-drug-information/abstract-text/6453536/pubmed\" target=\"_blank\" id=\"6453536\">6453536</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guay DR. Drug treatment of paraphilic and nonparaphilic sexual disorders. <i>Clin Ther</i>. 2009;31(1):1-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/medroxyprogesterone-acetate-drug-information/abstract-text/19243704/pubmed\" target=\"_blank\" id=\"19243704\">19243704</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hsia J, Langer RD, Manson JE, et al, &quot;Conjugated Equine Estrogens and Coronary Heart Disease: The Women's Health Initiative,&quot; <i>Arch Intern Med</i>, 2006, 166(3):357-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/medroxyprogesterone-acetate-drug-information/abstract-text/16476878/pubmed\" target=\"_blank\" id=\"16476878\">16476878</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/medroxyprogesterone-acetate-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Loprinzi CL, Levitt R, Barton D, et al. Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. <i>J Clin Oncol</i>. 2006;24(9):1409-1414.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/medroxyprogesterone-acetate-drug-information/abstract-text/16505409/pubmed\" target=\"_blank\" id=\"16505409\">16505409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/medroxyprogesterone-acetate-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    M&oslash;rch LS, L&oslash;kkegaard E, Andreasen AH, Kr&uuml;ger-Kjaer S, Lidegaard O. Hormone therapy and ovarian cancer. <i>JAMA</i>, 2009, 302(3):298-305.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/medroxyprogesterone-acetate-drug-information/abstract-text/19602689/pubmed\" target=\"_blank\" id=\"19602689\">19602689</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    North American Menopause Society (NAMS). The 2012 hormone therapy position statement of: The North American Menopause Society. <i>Menopause</i>. 2012;19(3):257-271.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/medroxyprogesterone-acetate-drug-information/abstract-text/22367731/pubmed\" target=\"_blank\" id=\"22367731\">22367731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24286192\"></a>Orbo A, Vereide A, Arnes M, et al. Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial. <i>BJOG</i>. 2014;121(4):477-486.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/medroxyprogesterone-acetate-drug-information/abstract-text/24286192/pubmed\" target=\"_blank\" id=\"24286192\">24286192</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Practice Committee of the American Society for Reproductive Medicine (ASRM). Treatment of pelvic pain associated with endometriosis: a committee opinion. <i>Fertil Steril</i>. 2014;101(4):927-935.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/medroxyprogesterone-acetate-drug-information/abstract-text/24630080/pubmed\" target=\"_blank\" id=\"24630080\">24630080</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Provera (medroxyprogesterone acetate) [prescribing information]. New York, NY; Pharmacia and Upjohn; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10986575\"></a>Reilly DR, Delva NJ, Hudson RW. Protocols for the use of cyproterone, medroxyprogesterone, and leuprolide in the treatment of paraphilia. <i>Can J Psychiatry</i>. 2000;45(6):559-563.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/medroxyprogesterone-acetate-drug-information/abstract-text/10986575/pubmed\" target=\"_blank\" id=\"10986575\">10986575</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rossouw JE, Anderson GL, Prentice RL, et al, &ldquo;Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principle Results From the Women's Health Initiative Randomized Controlled Trial,&rdquo;<i>JAMA</i>, 2002, 288(3):321-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/medroxyprogesterone-acetate-drug-information/abstract-text/12117397/pubmed\" target=\"_blank\" id=\"12117397\">12117397</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/medroxyprogesterone-acetate-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shumaker SA, Legault C, Rapp SR, et al, &ldquo;Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study: A Randomized Controlled Trial,&rdquo; <i>JAMA</i>, 2003, 289(20):2651-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/medroxyprogesterone-acetate-drug-information/abstract-text/12771112/pubmed\" target=\"_blank\" id=\"12771112\">12771112</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sitruk-Ware R and Nath A, &quot;Metabolic Effects of Contraceptive Steroids,&quot; <i>Rev Endocr Metab Disord</i>, 2011, 12(2):63-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/medroxyprogesterone-acetate-drug-information/abstract-text/21538049/pubmed\" target=\"_blank\" id=\"21538049\">21538049</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tepper NK, Krashin JW, Curtis KM, Cox S, Whiteman MK. Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2016: Revised Recommendations for the Use of Hormonal Contraception Among Women at High Risk for HIV Infection. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(37):990-994. doi: 10.15585/mmwr.mm6637a6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/medroxyprogesterone-acetate-drug-information/abstract-text/28934178/pubmed\" target=\"_blank\" id=\"28934178\">28934178</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thibaut F, De La Barra F, Gordon H, et al, &ldquo;The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Paraphilias,&rdquo; <i>World J Biol Psychiatry</i>, 2010, 11(4):604-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/medroxyprogesterone-acetate-drug-information/abstract-text/20459370/pubmed\" target=\"_blank\" id=\"20459370\">20459370</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thigpen JT, Brady MF, Alvarez RD, et al, &ldquo;Oral Medroxyprogesterone Acetate in the Treatment of Advanced or Recurrent Endometrial Carcinoma: A Dose-Response Study by the Gynecologic Oncology Group,&rdquo; <i>J Clin Oncol</i>, 1999, 17(6):1736-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/medroxyprogesterone-acetate-drug-information/abstract-text/10561210/pubmed\" target=\"_blank\" id=\"10561210\">10561210</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23090535\"></a>Trimble CL, Method M, Leitao M, et al. Management of endometrial precancers. <i>Obstet Gynecol</i>. 2012;120(5):1160-1175.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/medroxyprogesterone-acetate-drug-information/abstract-text/23090535/pubmed\" target=\"_blank\" id=\"23090535\">23090535</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9600 Version 224.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709035\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F192012\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F192013\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F192035\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F192015\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F192028\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F192016\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F16317858\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F192017\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F191989\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F191974\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F48850266\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F191992\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132797\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F191991\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25730742\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F192043\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F191981\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F191995\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F191978\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F192030\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F191983\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F192007\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F191997\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F191998\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F191999\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F191987\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F191977\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F191994\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F191996\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F192000\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9600|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=medroxyprogesterone-acetate-patient-drug-information\" class=\"drug drug_patient\">Medroxyprogesterone acetate: Patient drug information</a></li><li><a href=\"topic.htm?path=medroxyprogesterone-acetate-pediatric-drug-information\" class=\"drug drug_pediatric\">Medroxyprogesterone acetate: Pediatric drug information</a></li></ul></div></div>","javascript":null}